Other medical therapies such as pegvisomant (GH receptor antagonist) and cabergoline (dopamine agonist) improve IGF-1 in a subset of patients with medication resistant acromegaly, but rates of biochemical non-remission range from 25–40% in this cohort [36–38]. The gene discussed is IGF1; the disease is acromegaly.